Brugada Syndrome 3

Common Name(s)

Brugada Syndrome 3

Brugada syndrome is characterized by an ST segment elevation in the right precordial electrocardiogram leads (so-called type 1 ECG) and a high incidence of sudden death in patients with structurally normal hearts. The syndrome typically manifests during adulthood, with a mean age of sudden death of 41 +/- 15 years, but also occurs in infants and children (summary by {1:Antzelevitch et al., 2005}). For a discussion of the genetic heterogeneity of Brugada syndrome, see BRGDA1 ({601144}).
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Brugada Syndrome 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Brugada Syndrome 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Brugada Syndrome 3" returned 9 free, full-text research articles on human participants. First 3 results:

Two novel Brugada syndrome-associated mutations increase KV4.3 membrane expression and function.
 

Author(s): Tao You, Weike Mao, Benzhi Cai, Faqian Li, Haodong Xu

Journal: Int. J. Mol. Med.. 2015 Jul;36(1):309-15.

 

The human cardiac fast transient outward K+ channel is composed of the KV4.3 α subunit encoded by KCND3 and the K+ channel‑interacting protein 2 (KChIP2) β subunit, and determines the early repolarization of the action potential (AP). Two human mutations (G600R and L450F) in KV4.3 ...

Last Updated: 10 Jun 2015

Go To URL
Characterization of SEMA3A-encoded semaphorin as a naturally occurring Kv4.3 protein inhibitor and its contribution to Brugada syndrome.
 

Author(s): Nicole J Boczek, Dan Ye, Eric K Johnson, Wei Wang, Lia Crotti, David J Tester, Federica Dagradi, Yuka Mizusawa, Margherita Torchio, Marielle Alders, John R Giudicessi, Arthur A M Wilde, Peter J Schwartz, Jeanne M Nerbonne, Michael J Ackerman

Journal: Circ. Res.. 2014 Aug;115(4):460-9.

 

Semaphorin 3A (SEMA3A)-encoded semaphorin is a chemorepellent that disrupts neural patterning in the nervous and cardiac systems. In addition, SEMA3A has an amino acid motif that is analogous to hanatoxin, an inhibitor of voltage-gated K(+) channels. SEMA3A-knockout mice exhibit an ...

Last Updated: 1 Aug 2014

Go To URL
SCN5A mutations associated with overlap phenotype of long QT syndrome type 3 and Brugada syndrome.
 

Author(s): Haruaki Nakaya

Journal: Circ. J.. 2014 ;78(5):1061-2.

 

Last Updated: 28 Apr 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Brugada Syndrome 3" returned 0 free, full-text review articles on human participants.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Worm Study: Modifier Genes in Sudden Cardiac Death
 

Status: Recruiting

Condition Summary: Brugada Syndrome; Long QT Syndrome 3

 

Last Updated: 13 May 2015

Go to URL